Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + ibrutinib
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of rituximab and ibrutinib is an FDA-approved, chemotherapy-free regimen for the treatment of certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström's macroglobulinemia. Ibrutinib is a first-in-class, oral small-molecule inhibitor of Bruton's tyrosine kinase (BTK), which disrupts B-cell receptor signaling critical for malignant B-cell proliferation and survival. Rituximab is a monoclonal antibody targeting the CD20 antigen on B-cells, leading to cell lysis through immune-mediated mechanisms. The combination has demonstrated improved progression-free survival compared to standard regimens in clinical trials and offers a non-chemotherapy option for patients with these hematologic cancers[1][2][4][8].
- Brand names
- Imbruvica + Rituxan
- Other names
- rituximab + ibrutinibImbruvica plus Rituxan
02
Targets
BTK (Bruton tyrosine kinase)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on rituximab + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + ibrutinib.